capital raising, page-23

Surely the priority is getting backing to pursue the necessary hurdles. There's clearly no suitable deals on the table that are worth accepting, hence the dilution and going it alone. The positive to come from it is if and when the trials come back with more wonderful results we will be a very much sought after battler with even more chance of more than one pharma in hot pursuit.
The results will never be more important than the next one's.